InvestmentMay 11, 2026, 04:03 PM
Aura Biosciences Secures $280.8M Equity Financing; Appoints New CEO
AI Summary
Aura Biosciences reported its first quarter 2026 financial results, highlighted by a significant oversubscribed equity financing that raised $280.8 million in net proceeds, extending its cash runway into the second half of 2028. The company also announced the appointment of Natalie Holles as its new Chief Executive Officer and President. Clinical trial progress continues, with the Phase 3 CoMpass trial for early choroidal melanoma advancing toward enrollment completion by mid-2026 and topline data anticipated in the second half of 2027.
Key Highlights
- Aura Biosciences secured $280.8 million in net proceeds from an oversubscribed equity financing.
- Cash position is expected to fund operations into the second half of 2028.
- Natalie Holles was appointed Chief Executive Officer and President, effective April 30, 2026.
- Phase 3 CoMpass trial for early choroidal melanoma is advancing toward enrollment completion by mid-2026, with topline data expected in 2H 2027.
- Q1 2026 cash and cash equivalents and marketable securities totaled $114.7 million as of March 31, 2026.
- Q1 2026 research and development expenses increased to $28.0 million from $23.3 million in Q1 2025.
- Q1 2026 general and administrative expenses increased to $6.9 million from $5.7 million in Q1 2025.
- Q1 2026 net loss was $33.7 million, compared to $27.5 million in Q1 2025.